Maternal characteristics most strongly associated with preterm birth were country of residence, maternal HIV clinical disease stage at enrollment and at labor/delivery, maternal plasma HIV-1 RNA concentration at enrollment, diabetes, mode of delivery, and hypertension (Table 1). With regard to maternal disease stage, mothers who had progressed to AIDS had the highest proportion of preterm infants (17.9%). When considering maternal plasma HIV-1 RNA concentration, mothers with < 1000 copies/ml at enrollment had the lowest proportion of infants with preterm birth (5.8%). Diabetic mothers had significantly higher rates of preterm births (25%) than those without diabetes (8.0%). When considering hypertension, mothers with pre-eclampsia/eclampsia or with chronic hypertension had the highest proportions of preterm infants (54.5% and 16.7%, respectively). Finally, those who delivered by cesarean section (either ECS or NECS) had higher rates of preterm birth (10.8% and 14.7%, respectively) than those who delivered vaginally (3.4%). Nonetheless, the mean gestational age for those infants who were born by cesarean section was 38.4 weeks, with a median of 38 weeks. Among women with ECS, the most frequent indication was prevention of mother-to-child transmission of HIV (47%), followed by repeat cesarean section (25%). The most common indication for NECS was prevention of mother-to-child transmission of HIV-1 (32%), followed by prolonged rupture of membranes (13%).
Variables included in multivariable modeling for LBW were country of residence, most complex ART regimen received for ≥ 28 days during pregnancy, HIV clinical classification at enrollment and at labor and delivery, plasma HIV-1 RNA concentration at enrolment, tobacco use during pregnancy, reason for receipt of ART during pregnancy, history of preterm birth, maternal diabetes, adjusted BMI, mode of delivery, and hypertension. Estimated odds ratios (OR) and confidence intervals (CI), both unadjusted and adjusted, for the variables included in the final model are shown in Table 2. After adjustment, mothers receiving HAART/PI did not have a statistically significant increased risk of having a LWB infant compared with mothers receiving 1–2 NRTI (adjusted OR, 1.5; 95% CI, 0.7–3.2). Independent risk factors for LBW were pre-eclampsia/eclampsia, NECS, maternal diabetes, and maternal underweight.
Variables included in multivariable modeling for preterm birth were country of residence; most complex ART regimen received for ≥ 28 days during pregnancy; HIV-1 clinical classification at enrollment and at labor and delivery; plasma HIV-1 RNA concentration at enrollment and hospital discharge; maternal diabetes; adjusted BMI; mode of delivery; and hypertension. Estimated OR and CI for the variables included in the final model are shown in Table 3. Although the most complex maternal ART regimen for ≥ 28 days during pregnancy did not enter the model in the stepwise selection or backwards elimination regression modeling, it was forced into the model (since the intended analysis was to evaluate the association of maternal ART regimens and preterm birth). After adjustment, HAART/PI was not associated with a statistically significant increased likelihood of preterm birth compared with receipt of 1–2 NRTI: adjusted OR, 1.1 (95% CI, 0.5–2.8). Independent risk factors for preterm birth were pre-eclampsia/eclampsia, cesarean delivery, maternal diabetes, and maternal underweight.
In our analysis of data regarding HIV-1-infected women and their infants at multiple clinical sites in Latin America and the Caribbean, the highest incidence of LBW and of preterm birth was noted among women whose most complex regimen during pregnancy contained a PI. There was an increased risk of preterm birth and LBW among women whose most complex regimen contained a PI compared with those receiving 1–2 NRTI. However, this increased risk was not statistically significant in either the unadjusted or the adjusted analyses. The wide CI values reflect the small number of outcome events observed.
Studies of HIV-1-infected women conducted before the introduction of ART prophylaxis or treatment during pregnancy suggested that HIV-1-infected women were at increased risk of adverse infant outcomes, including preterm birth [7–9] and LBW [8–12]. In addition, studies in which HIV-1-infected women either received or did not receive one or more antiretroviral drugs during pregnancy have continued to demonstrate a relationship between maternal HIV disease stage (e.g., as manifested by lower CD4 cell counts) and the risk of preterm birth and LBW [8,13,19].
Our study of HIV-1-infected women and their infants in Latin America and the Caribbean did not demonstrate an increased risk of preterm birth and LBW with PI-containing regimens. However, it is important to note that, in contrast to previous studies, the reference group for our analyses was women who received 1–2 NRTI (and not women without any ART exposure during pregnancy, because of the small size of this group).
Independent risk factors for both preterm birth and LBW included eclampsia and pre-eclampsia. An association between HAART and an increased risk of pre-eclampsia has been observed [22–24], and the association of hypertension and pre-eclampsia with increased risks of preterm birth and LBW is well recognized [25,26].
The overall rates of preterm birth and LBW among the HIV-1-infected women in this cohort are much lower than the rates reported in other studies of HIV-1-infected women and their infants. These lower rates could be related to a lower frequency of cesarean section deliveries, but also to other factors, such as the lower rate of alcohol and illegal substance use during pregnancy compared with North American and European studies [18,19,21]. This lower rate of alcohol and substance use likely reflects the primary mode of HIV transmission in Latin America (heterosexual transmission) . The observed rate of preterm birth (8.4%) in our cohort of HIV-1-exposed infants is similar to that reported for the general population of infants in the Latin American countries represented in this study [36–41]. However, the observed rate of LBW (12.2%) in our cohort is higher than those reported for the general population of infants in Argentina (7%), Bahamas (7%), Brazil (10%), and Mexico (9%) .
Among the strengths of this study is the recruitment of a large number of study participants across several countries in Latin America and the Caribbean, and the prospective collection of data (minimizing the potential for recall bias), with a very low rate of loss to follow-up . However, this study has limitations. We did not have information regarding adherence to ART. Also, at the beginning of this study, we did not collect data on the duration of receipt of ART prior to pregnancy and, therefore, we could not assess the importance of this factor as it relates to adverse infant outcomes. Although we did have information regarding the duration of ART exposure during pregnancy and the number of regimens received during pregnancy, the relatively small number of events among women receiving different ART regimens precluded further analyses evaluating duration of receipt or number of regimens and the outcomes of interest (preterm birth and LBW). Because of the small number of infants at VLBW, analyses of this as an outcome variable were not conducted. In terms of the multivariable modeling, the number of outcome events was relatively small in some instances (e.g., maternal hypertension) given the total number of parameters being estimated, affecting the precision of models' estimates (leading to wide CI values). Consequently, the risk estimates associated with the independent risk factors, particularly hypertension and diabetes, should be interpreted with caution as they were included in the model primarily for adjustment purposes and not risk estimation.
We conclude that among HIV-1-infected women in Latin America and the Caribbean, receipt of a PI-containing regimen during pregnancy is not associated with an increased risk of LBW and preterm birth compared with regimens containing only 1–2 NRTI. However, it is important to continue to monitor HIV-1-infected women and their children, especially the uninfected children, for potential adverse events associated with maternal treatment of HIV-1 disease or with receipt of interventions to prevent mother-to-child transmission of HIV-1.
1. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis
2. Joao EC, Cruz ML, Menezes JA, Matos HJ, Calvet GA, d'Ippolito MM, et al
. Vertical transmission of HIV in Rio de Janeiro, Brazil. AIDS 2003; 17:1853–1855.
4. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al
. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484–494.
5. Nogueira SA, Abreu T, Oliveira R, Araujo L, Costa T, Andrade M, et al
. Successful prevention of HIV transmission from mother to infant in Brazil using a multidisciplinary team approach. Braz J Infect Dis 2001; 5:78–86.
6. Chersich MF, Gray GE. Progress and emerging challenges in preventing mother-to-child transmission. Curr Infect Dis Rep 2005; 7:393–400.
7. Taha TET, Dallabetta GA, Canner JK, Chiphangwi JD, Liomba G, Hoover DR, et al
. The effect of human immunodeficiency virus infection on birthweight and infant and child mortality in urban Malawi. Int J Epidemiol 1995; 24:1022–1029.
8. Ellis J, Williams H, Graves W, Lindsay MK. Human immunodeficiency virus infection is a risk factor for adverse perinatal outcome. Am J Obstet Gynecol 2002; 186:903–906.
9. Leroy V, Ladner J, Nyiraziraje, de Clercq A, Bazubagira A, van de Perre P, et al
. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992–1994. AIDS 1998; 12:643–650.
10. Markson LE, Turner BJ, Houchens R, Silverman NS, Cosler L, Takyi BK. Association of maternal HIV infection with low birth weight. J Acquir Immun Defic Syndr Hum Retrovirol 1996; 13:227–234.
11. Temmerman M, Plummer FA, Mirza NB, Ndinya-Achola JO, Wamola IA, Nagelkerke N, et al
. Infection with HIV as a risk factor for adverse obstetrical outcome. AIDS 1990; 4:1087–1093.
12. Mwanyumba F, Claeys P, Gaillard P, Verhofstede C, Chohan V, Mandaliya K, et al
. Correlation between maternal and infant HIV infection and low birth weight: a study in Mombasa, Kenya. J Obstet Gynaecol 2001; 21:27–31.
13. Dreyfuss ML, Msamanga GI, Spiegelman D, Hunter DJ, Urassa EJ, Hertzmark E, et al
. Determinants of low birth weight among HIV-infected pregnant women in Tanzania. Am J Clin Nutr 2001; 74:814–826.
14. Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, et al
. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS 2000; 14:1389–1399.
15. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18:2337–2339.
16. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al
. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12:F241–F247.
17. European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS
18. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al
. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863–1870.
19. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al
. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38:449–473.
20. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195–1201.
21. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr
22. Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, McG Thom SA, Hughes AD, et al
. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360:1152–1154.
23. European Collaborative Study. Pregnancy-related chanes in the longer-term management of HIV-infected women in Europe. Eur J Obstet Gynecol Reprod Biol
24. Suy A, Martinez E, Coll O, Lonca M, Palacio M, de Lazzari E, et al
. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20:59–66.
25. Xiao R, Sorensen TK, Williams MA, Luthy DA. Influence of pre-eclampsia on fetal growth. J Matern Fetal Neonatal Med 2003; 13:157–162.
26. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? Br J Obstet Gynaecol 2004; 111:298–302.
27. Attico NB, Meyer DJ, Bodin HJ, Dickman DS. Gestational age assessment. Am Fam Physician 1990; 41:553–560.
28. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard Score, expanded to include extremely premature infants. J Pediatr 1991; 119:417–423.
29. Dubowitz LM, Dubowitz V, Goldberg C. Clinical assessment of gestational age in the newborn infant. J Pediatr 1970; 77:1–10.
30. Capurro H, Konichezky S, Fonseca D, Caldeyro-Barcia R. A simplified method for diagnosis of gestational age in the newborn infant. J Pediatr 1978; 93:120–122.
31. Centers for Disease Control 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR
32. Ministerio de Salud y Ambiente de la Nación, Dirección Nacional de Salud Materno Infantil, Programa Materno Infantil, Provincia de Buenos Aires y la Dirección de Información de la Provincia de Neuquén. [Ministry of Health and Environment of the Nation, National Directorate of Maternal and Infant Health, Maternal and Infant Program of the Buenos Aires Province and the Directorate of Information of the Province of Neuquén.] Programa Nutri Desarrollado en EpiInfo
. [Nutri Program, Developed in EpiInfo
.] Accessed 16 February 2006: http://www.msal.gov.ar/htm/Site/promin/UCMISALUD/utilidades/util.htm
33. Division of AIDS, National Institute of Allergy and Infectious Diseases. Table for Grading the Severity of Adult and Pediatric Adverse Events,
version 1.0. Maryland, MD: National Institute of Allergy and Infectious Diseases; 2004. Accessed 16 February 2006: http://rcc.tech-res-intl.com
34. Freeman GH, Halton JH. Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951; 38:141–149.
35. Read JS, Burchett S, Shapiro D, Pollack H, McNamara J, Ortiz-Pujols S, et al
. Low birth weight and preterm birth among infants of HIV-infected mothers according to maternal receipt of antiretroviral drug(s) during pregnancy: PACTG 367. 41st Annual Meeting of the Infectious Diseases Society of America
. San Diego, October 2003 [abstract 677].
36. Althabe F, Carroli G, Led R, Belizán JM, Althabe O. El parto pretérmino: detección de riesgos y tratamiento preventives. Rev Panam Salud Pública 1999; 5:373–385.
37. Hortal BL, Victoria CG, Menezes AM, Halpern R, Barros FC. Low birthweight, preterm birth and intrauterine growth retardation in relation to maternal smoking. Paediatr Perinat Epidemiol 1997; 2:140–151.
38. Barros FC, Victora CG, Barros AJ, Santos IS, Albernaez E, Matijasevich A, et al
. The challenge of reducing neonatal mortality in middle-income countries: findings for three Brazilian birth cohorts in 1982, 1983 and 2004. Lancet 2005; 365:847–854.
40. Canto-de Cetina T, Polanco-Reyes L, Fernández-González V, Ruiz-García S. Infección por Chlamydia trachomatis
en usuarias de dos clínicas de planificación familiar. Salud Publ Méx 2003; 45(Suppl 5):S657–S661.
41. Quiroga Cantú M, García R, Reyes de los Santos EA. Morbimortalidad perinatal. Bol méd Hosp Infantil de México 1979; 36:871–884.
42. UNICEF. Low Birthweight: Country, Regional and Global Estimates, Table 3
: UNICEF/WHO Estimates of the Incidence of Low Birthweight, 2000
. New York: United Nations Children's Fund, Strategic Information Unit, Division of Policy and Planning; 2004:10–18.
Principal investigators, study coordinators, coordinating center representatives, and NICHD staff include: Argentina: Buenos Aires: Marcelo H. Losso, Adriana S. Durán, Silvina Ivalo, Alejandro Hakim (Hospital General de Agudos José María Ramos Mejía); Pedro Cahn, Maria Rolon (Hospital Juan Fernandez); Edgardo Szyld, Eduardo Warley (Hospital Diego Paroissien); Mariana Ceriotto, Susana Luciano, Maria Laura Collins (Hospital de Agudos Dra. Cecilia Grierson); Bahamas: Nassau: Perry Gomez, Percival McNeil, Marva Jervis, Chanelle Diggiss, Rosamae Bain (Princess Margaret Hospital); Brazil: Belo Horizonte: Jorge Pinto, Victor Melo, Fabiana Kakehasi (Universidade Federal de Minas Gerais); Caxias do Sul: Ricardo de Souza, Jose Mauro Madi (Universidade de Caxias do Sul/Hospital Geral de Caxias do Sul); Ricardo de Souza, Rosangela Boff, Ruti Pipi (Universidade de Caxias do Sul/Ambulatório Municipal de DST/AIDS); Porto Alegre: Ricardo de Souza, Breno Riegel Santos, Rita Lira (Universidade de Caxias do Sul/Hospital Conceicao); Ricardo de Souza, Rosana da Fonseca, Mario Peixoto, Rita Lira (Universidade de Caxias do Sul/Hospital Femina); Ribeirão Preto: Marisa M Mussi-Pinhata, Geraldo Duarte, Alessandra C. Marcolin (HCFMRP-USP); Rio de Janeiro: Marcos Machado D'Ippolito, Esau Custodio Joao, Jacqueline Menezes, Guilherme Amaral Calvet (Hospital dos Servidores do Estado); Sao Paulo: Regina Celia de Menezes Succi, Prescilla Chow Lindsey (Federal University of Sao Paulo); Mexico: Mexico City: Javier Ortiz Ibarra, Ricardo Figueroa-Damian, Guadalupe Noemi Plazola - Camacho (Instituto Nacional de Perinatología); Data Management and Statistical Center: René Gonin, James Korelitz, Susan Truitt, Roslyn Hennessey, Yolanda Bertucci, Laura Freimanis, D. Robert Harris, Julianne Byrne (Westat, Rockville, MD, USA); NICHD: Lynne Mofenson, Jack Moye, Jennifer S. Read, Leslie Serchuck, Heather Watts (National Institute of Child Health and Human Development, Bethesda, Maryland, USA). Supported by NICHD Contract #N01-HD-3-3345.
43. Read J, Losso M, Pinto J, Joao E, Duarte G, Chang D, et al
. A prospective cohort study of HIV-1-infected pregnant women and their infants in Latin America and the Caribbean: The NICHD International Site Development Initiative Perinatal Study
. 12th Conference on Retroviruses and Opportunistic Infections
. Boston, February 2005 [abstract 790].